Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body’s receptors for GIP and GLP-1, two natural incretin hormones.

The usual starting dose for Tirzepatide is 2.5 mg once weekly for 4 weeks. After the first 4 weeks, you may increase the dose by 2.5 mg increments every 4 weeks until the desired goal is reached. Monitor weight loss and side effects.

GIP has decreased food intake and increased energy expenditure, resulting in weight reductions. Combined with a GLP-1 receptor agonist, it has a more significant effect on glucose and body weight effects.

• Substantial A1C reductions.
• Boosted weight loss.
• Improvements in cardiometabolic measures.
• Reduce appetite.